SCHEMBL5143410

SCHEMBL5143410

Cc1cc(C(=O)O)ccc1-c1ccc(C=C2NC(=O)NC2=O)o1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPM1G O15355 1/20 0.62
PTPN1 P18031 1/20 0.62
PTPN7 P35236 1/20 0.62
PTPN5 P54829 1/20 0.62
PTPRO Q16827 1/20 0.62
PTPN22 Q9Y2R2 1/20 0.62
POLB P06746 7/20 0.61
L3MBTL1 Q9Y468 7/20 0.61
KDM4E B2RXH2 5/20 0.61
TDP1 Q9NUW8 4/20 0.61
MAPT P10636 4/20 0.61
ALDH1A1 P00352 4/20 0.61
APEX1 P27695 3/20 0.61
RECQL P46063 3/20 0.61
NPSR1 Q6W5P4 1/20 0.61
CTDSP1 Q9GZU7 4/20 0.59
APOBEC3A P31941 2/20 0.59
APOBEC3G Q9HC16 2/20 0.59
IDH1 O75874 1/20 0.59
MEN1 O00255 7/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5143408 1.00 PPM1G (0.62) PPM1GPTPN1PTPN7PTPN5PTPRO
SCHEMBL5143034 0.91 POLB (0.65) PPM1GPTPN1PTPN7PTPN5PTPRO
SCHEMBL5143032 0.91 POLB (0.65) PPM1GPTPN1PTPN7PTPN5PTPRO
SCHEMBL3362481 0.81 GSK3A (0.77) POLBL3MBTL1KDM4ETDP1MAPT
SCHEMBL3362480 0.81 GSK3A (0.77) POLBL3MBTL1KDM4ETDP1MAPT
SCHEMBL12990390 0.81 GSK3A (0.77) POLBL3MBTL1KDM4ETDP1MAPT
SCHEMBL12812667 0.79 INSR (0.69) PPM1GPTPN1PTPN7PTPN5PTPRO
SCHEMBL12990771 0.79 GSK3A (0.79) POLBL3MBTL1KDM4ETDP1MAPT
SCHEMBL3365349 0.79 GSK3A (0.79) POLBL3MBTL1KDM4ETDP1MAPT
SCHEMBL3365346 0.79 GSK3A (0.79) POLBL3MBTL1KDM4ETDP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1718308-A4 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORP (CA) 2007-07-18 EP disclosed
EP-1718308-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PainCeptor Pharma Corp. (CA) 2006-11-08 EP disclosed
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2005-12-22 US disclosed
WO-2005076695-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 PPM1G 2676/4885PTPN1 2566/4885PTPN7 1852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.